Association Factors for CT Angiography Spot Sign and Hematoma Growth in Korean Patients with Acute Spontaneous Intracerebral Hemorrhage: A Single-Center Cohort Study

Byung Hoo Moon, M.D., Dong-Kyu Jang, M.D., Young-Min Han, M.D., Ph.D., Kyung-Sool Jang, M.D., Ph.D., Ryoong Huh, M.D., Ph.D., Young Sup Park, M.D., Ph.D.

Department of Neurosurgery, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea

Objective: This study was conducted to clarify the association factors and clinical significance of the CT angiography (CTA) spot sign and hematoma growth in Korean patients with acute intracerebral hemorrhage (ICH).

Methods: We retrospectively collected the data of 287 consecutive patients presenting with acute ICH who arrived within 12 hours of ictus. Baseline clinical and radiological characteristics as well as the mortality rate within one month were assessed. A binary logistic regression was conducted to obtain association factors for the CTA spot sign and hematoma growth.

Results: We identified a CTA spot sign in 40 patients (13.9%) and hematoma growth in 78 patients (27.2%). An elapsed time to CT scan of less than 3 hours (OR, 5.14; 95% CI, 1.76–15.02; p=0.003) was associated with the spot sign. A CTA spot sign (OR, 5.70; 95% CI, 2.70–12.01; p<0.001), elevated alanine transaminase (GPT) level >40 IU (OR, 2.01; 95% CI, 1.01–4.01; p=0.047), and an international normalized ratio ≥1.8 or warfarin medication (OR, 4.92; 95% CI, 1.31–18.50; p=0.019) were associated with hematoma growth. Antiplatelet agent medication (OR, 4.92; 95% CI, 1.31–18.50; p=0.019) was significantly associated with hematoma growth within 6 hours of ictus.

Conclusion: As previous other populations, CTA spot sign was a strong predictor for hematoma growth especially in hyper-acute stage of ICH in Korea. Antithrombotics medication might also be associated with hyper-acute hematoma growth. In our population, elevated GPT was newly identified as a predictor for hematoma growth and its effect for hematoma growth is necessary to be confirmed through a further research.

Key Words: Intracerebral hemorrhage · CT angiography · Spot sign · Hematoma growth · Antithrombotics · Alanine transaminase.
MATERIALS AND METHODS

Populations and study design

From 2005–2012, we collected retrospective data for consecutive patients with spontaneous supratentorial ICH that were admitted to the Stroke and Cerebrovascular Center at our hospital, which serves a population of approximately 560,000. The institutional review boards at our hospital approved the current study. The inclusion criteria were the following: 1) age ≥18 years old and 2) CTA-proven spontaneous supratentorial hemorrhage. Patients with a cerebral aneurysm rupture, traumatic ICH, tumor bleeding, arteriovenous malformation-related ICH, dural arteriovenous fistula associated ICH, cavernous hemangioma, Moyamoya disease, Moyamoya syndrome, probable Moyamoya disease, venous thrombosis, hemorrhagic transformation after cerebral infarction, ICH after thrombolysis, or posterior reversible leukoencephalopathy were excluded. Out of 713 eligible patients with intracerebral hemorrhage from 2005–2012, 287 patients were excluded due to secondary causes of ICH. Of the remaining 426 ICH patients, we excluded those who arrived at our hospital more than 12 hours from ictus, as well as those who did not undergo CTA at admission or at follow-up to determine the factors associated with a spot sign in ICH at the acute stage (Fig. 1).

Baseline characteristics, laboratory and radiologic profiles

We scrutinized baseline characteristics of the patients including onset age, hypertension, stroke history, antiplatelet drug medication, warfarin medication, reasons for antithrombotics medication, and aggravation of neurologic status indicated by a decrease in the Glasgow Coma Scale (GCS) score ≥2 or a decrease in the National Institutes of Health Stroke Scale ≥4 within 24 hours of ictus. The hematocrit, international normalized ratio (INR), platelet count, and alanine transaminase (GPT) levels were recorded. Radiologic profiles were also assessed to determine the location of the hemorrhage, volume of the ICH (using the ABC/2 method), location of the spot sign on an enhanced computed tomography (CT) image, intraventricular hemorrhage (IVH) degree (indicating the number of hemorrhage-involved ventricles) and the time from ictus until the CT scan was performed. The location of the hemorrhage was classified as lobar or deep-seated. Hemorrhages originating from the basal ganglia, thalamus, or corpus callosum were categorized as deep-seated hemorrhages. The spot sign was defined as a contrast enhancement focus that was greater than 1 mm in size within the ICH on the axial image of the CTA regardless of the shape of the enhancement (Fig. 2). Hematoma growth was defined as an absolute increase >6 mL or a relative increase >33% compared with the initial CT image, or an increased IVH determined on a follow-up CT scan within 14 days of ictus.

CT protocol, ICH management, and outcome measurements

All patients presenting with intracranial hemorrhage arrived at our emergency department and underwent brain CT angiography with a multi-detector 64 slice CT scanner (Aquilion, Toshiba Medical System Corporation, Tokyo, Japan). Secondary causes of ICH were thoroughly ruled out through further studies, such as digital subtraction angiography, brain MR imaging, or cerebral venography. A non-contrast CT examination was performed using an axial technique (120 kV, 70 mA, and 5 mm slice thickness reconstruction); a multidetector CT scan was subsequently conducted by scanning from the base of the C7 vertebral body to the vertex using an axial technique (0.641 pitch, 0.5-mm collimation, 350 maximal mA, 120 kVp, 2 mm slice thickness) with 80–100 mL of iodinated contrast material administered using a power injector at 3–4 mL per second into the antecubital vein with an approximately 16- to 18-second delay between the onset of contrast injection and the start of scanning. Protamine sulfate and vitamin K were administered as antidotes to patients with heparin-related and warfarin-related
hemorrhage to induce hemostasis. Aminomethylbenzoic acid (150 mg) was routinely injected with normal saline fluid for 3 days. Blood pressure was reduced to <140 mm Hg for systolic blood pressure (SBP) and <90 mm Hg for diastolic blood pressure (DBP) through nicardipine or labetalol IV injections for patients with an initial SBP <180 mm Hg or DBP <110 mm Hg. In the case of an initial SBP >180 mm Hg or DBP >110 mm Hg, the initial SBP or DBP was reduced by approximately 15%. Brain CT or MR scanning was followed-up routinely as follows: 1) between 24 and 72 hours from admission, 2) 4 hours later if a spot sign was found on the initial enhanced CT image, 3) immediately if neurological deterioration occurred, or 4) 7 to 14 days from admission. The hematoma volume was calculated using the formula ABC/2, where A is the greatest diameter on the largest hematoma image, B is perpendicular to line A and C is the vertical depth of the hematoma. The time to reach the target blood pressure according to our center's guidelines was measured. The surgical treatment of supratentorial ICH was conducted according to our center's guidelines.

Screening was conducted by a neurological surgeon, and baseline characteristics were investigated by two training residents. Clinical outcomes were assessed by two trained stroke nurses who were not involved in the current study and unaware of the baseline treatments.

Statistics

For the descriptive analysis, all baseline values are displayed as percentage, and the mean value±standard deviation or the median with the interquartile range are shown. Normality tests were performed on all potential continuous variables, and t-tests were conducted to confirm intergroup differences in cases with normal distributions. For categorical variables, a chi-square test was performed between independent two groups. A binary logistic regression method was used to calculate association predictors for the CTA spot sign and hematoma growth. If the p value of a potential factor was less than 0.05 in the univariable analysis, it was entered into the multivariable analysis model, but backward-eliminated to p>0.1. The Hosmer-Lemeshow test was used as a goodness-of-fit test. The Mann-Whitney U test was used to compare variables between two groups with non-normal distributions. p values of less than 0.05 were considered statistically significant. Two-tailed methods were used in all statistical analyses. All statistical calculations were performed using SAS version 9.13 (SAS Institute Inc., Cary, NC).

RESULTS

The mean age of the 287 patients was 61.7 (standard deviation 12.7) years. Of these patients, 161 (56.1%) were male and 126 (43.9%) were female. Hypertension was identified in 151 (52.6%), diabetes in 32 (11.5%), hyperlipidemia or statin medication in 62 (21.6%), current smoking in 103 (35.9%), daily alcohol consumption at an amount >60 g in 41 (13.4%), antiplatelet agent medication in 51 (17.8%), warfarin medication in 7 (2.4%), ischemic stroke history in 11 (3.8%), and hemorrhagic stroke in 6 (2.1%) patients. There were 73 (25.4%) patients with GCS scores of less than 12. Twenty (7.0%) patients deteriorated neurologically within 24 hours of ictus. Forty (13.9%) patients had lobar hemorrhage and 247 (86.1%) had deep-seated hemorrhage. The median hematoma volume was 16 mL (range: 1–160 mL). IVH with or without ICH was noted in 128 (44.6%) patients. The CTA spot sign was identified in 40 (13.9%) patients. Among the 40 patients with the spot sign, 27 (67.5%) had 1 spot, 10 (25%) had 2 spots, 1 (2.5%) had 3 spots, and 2 (5%) had 4 spots. The median Hounsfield units of the spot sign was 152 (range: 74–297). Thirty six (90%) of 40 spot signs were identified within 3 hours from ictus. Hematoma growth within 14 days was identified in 78 (27.2%) patients. Hematoma evacuation was performed in 108 (37.6%) patients. The thirty-day mortality rate was 11.8%. Baseline demography is described in detail in Table 1, 2.

Predictors for CTA spot sign and hematoma growth

In the univariable analysis, reasons for antithrombotics medication, time from ictus to CT scan <3 hours, hemorrhagic volume ≥30 mL, and intraventricular extension were significantly associated with a CTA spot sign (Table 1). These variables, except for antithrombotics medication due to heterogeneous disease entity, were entered into the final multivariable binary logistic regression analysis model (Table 3). An INR ≥1.8, alanine aminotransferase ≥40 IU, hemorrhage volume ≥30 mL, and a spot sign...
Table 1. Clinical, laboratory, and radiologic characteristics of acute ICH patients with or without CTA spot sign

| Factors                              | Spot sign (+) (n=40) | Spot sign (-) (n=247) | p value |
|--------------------------------------|----------------------|-----------------------|---------|
| Age (years), mean±SD                 | 60.7±13.7            | 71.9±13.7             | 0.58    |
| Hypertension, n (%)                  | 25 (62.5)            | 126 (51.0)            | 0.17    |
| Antithrombotics, n (%)               | 11 (27.5)            | 44 (17.8)             | 0.14    |
| Antiplatelet                         | 9 (22.5)             | 42 (17.0)             | 0.39    |
| Warfarin                             | 2 (5.0)              | 5 (2.0)               | 0.25    |
| Reasons for antithrombotic medication, n (%) |                     |                      |         |
| Ischemic stroke                      | 1 (2.5)              | 10 (4.0)              |         |
| Ischemic heart disease               | 3 (7.5)              | 3 (1.2)               |         |
| Atrial fibrillation or other cardiac disease | 3 (7.5)              | 5 (2.0)              |         |
| Others†                              | 4 (10.0)             | 26 (10.5)             |         |
| Hemorrhagic stroke, n (%)            | 1 (2.5)              | 5 (2.0)               | 0.59    |
| Time from ictus to CT scan <3 hours, n (%) | 36 (90.0)            | 157 (63.6)            | 0.001   |
| Hematocrit (%)                       | 39.2±6.0             | 39.7±5.5              | 0.58    |
| INR ≥1.8, n (%)                      | 2 (5.0)              | 6 (2.4)               | 0.30    |
| GPT (IU), mean±SD                    | 32.6±28.7            | 28.5±30.5             | 0.42    |
| Location of hematoma, n (%)          |                      |                      | 0.62    |
| Deep                                 | 36 (90.0)            | 212 (85.3)            |         |
| Lobar                                | 4 (10.0)             | 35 (14.2)             |         |
| Hemorrhage volume ≥30 mL, n (%)      | 19 (47.5)            | 73 (29.6)             | 0.024   |
| Intraventricular extension, n (%)    | 25 (62.5)            | 103 (41.7)            | 0.014   |
| Time to target blood pressure (hour), n (%)† |                 |                      | 0.41    |
| <1                                   | 23 (57.5)            | 153 (61.9)            |         |
| ≥ 1 and <3                          | 13 (32.5)            | 66 (26.7)             |         |
| ≥ 3 and <6                          | 2 (5.0)              | 23 (9.3)              |         |
| ≥6                                   | 2 (5.0)              | 5 (2.0)               |         |
| Neurologic deterioration, n (%)      | 5 (12.5)             | 15 (6.1)              | 0.13    |
| Hematoma growth, n (%)               | 25 (62.5)            | 53 (21.5)             | <0.001  |
| Hematoma evacuation, n (%)           | 29 (72.5)            | 79 (32.0)             | <0.001  |
| Death within 1 month, n (%)          | 8 (20.0)             | 26 (10.5)             | 0.085   |

†Primary prevention of cerebrovascular or cardiovascular or peripheral vessel event. Time from arrival to goal of blood pressure according to our center’s guideline. SD : standard deviation, INR : international normalized ratio, GPT : alanine transaminase.

were significantly associated with hematoma growth (Table 2) in univariable analysis and then entered into multivariable logistic regression analysis (Table 4). Warfarin medication and hematocrit were also entered into a multivariable model due to a borderline probability for hematoma growth (p<0.1) (Table 2, 4).

After adjustment of potential factors, time from ictus to CT scan <3 hours was the only factor identified as a significant predictor for the CTA spot sign (OR, 5.14; 95% CI, 1.76–15.02; p=0.068). Intraventricular extension was revealed as a borderline association factor (OR, 1.96; 95% CI, 0.95–4.05; p=0.002) for the CTA spot sign (Table 3). On the other hand, a CTA spot sign (OR, 5.70; 95% CI, 2.70–12.01; p=0.001) and elevated GPT level >40 IU (OR, 2.01; 95% CI, 1.01–4.01; p=0.047) were independent predicting factors of hematoma growth. Though an INR of 1.8 or greater was marginally related to hematoma growth in the multivariable binary logistic regression model 1, an INR ≥1.8 or warfarin medication was significantly associated with hematoma growth in model 2 (Table 4).

In the subgroup analysis of 78 hematoma growth patients, the time from ictus to hematoma growth was shorter in the group with spot signs than in the group without any spot sign (Fig. 3). In addition to a spot sign (OR, 3.47; 95% CI, 1.15–10.48; p=0.027) and large hemorrhage volume of 30 mL or more (OR, 3.63; 95% CI, 1.25–10.57; p=0.018), antiplatelet medication (OR, 4.92; 95% CI, 1.31–18.50; p=0.019) showed a significant association with hematoma growth within 6 hours from ictus in multivariable regression analysis (Table 5).

DISCUSSION

Our study showed that an elapsed time from ictus to CT scan of 3 hours or less was an independent predictor for a CTA spot sign. Additionally, a CTA spot sign and elevated GPT level were independent predictors for hematoma growth of acute ICH patients in Korea. Elevated INR was marginally associated with hematoma growth, and antiplatelet medication was particularly related to hematoma growth within 6 hours of ictus.

Only an elapsed time to CT scan of 3 hours or less was strong-
spot sign was shorter than that without a CTA spot sign. Further in the present study, there was no difference in the occurrence of a CTA spot sign between deep and lobar hemorrhages (Table 1), and intraventricular extension showed a borderline association with the CTA spot sign (Table 3). In addition, Fig. 3 demonstrates that the time from ictus to hematoma growth of ICH with a CTA spot sign was shorter than that without a CTA spot sign. Furthermore, in hyper-acute ICH within 3 hours of ictus, there may be a high probability of the presence of a CTA spot sign, which leads to early hematoma growth.

Many recent studies have reported that a CTA spot sign may be a good radiologic indicator for hematoma growth as well as intraventricular extension. In a large epidemiological study in Asian countries, many studies to be risk factors for hematoma growth in acute cerebral hemorrhage, but with the CTA spot sign. The CTA spot sign has also been identified as an association factor for hematoma growth. In a large epidemiological study in Asian countries, GPT elevation was revealed to be associated with ICH development and poor outcome.

### Table 2. Clinical, laboratory, and radiologic characteristics of acute ICH patients with or without hematoma growth

| Factors                        | Hematoma growth (+) (n=78) | Hematoma growth (-) (n=209) | p value |
|--------------------------------|-----------------------------|------------------------------|---------|
| Age (years), mean±SD           | 61.2±13.6                   | 61.9±12.4                    | 0.67    |
| Hypertension, n (%)            | 37 (47.4)                   | 114 (54.5)                   | 0.28    |
| Antithrombotics, n (%)         | 16 (20.5)                   | 39 (18.7)                    | 0.72    |
| Antiplatelet                   | 14 (17.9)                   | 37 (17.7)                    | 0.96    |
| Warfarin                       | 4 (5.1)                     | 3 (1.4)                      | 0.09    |
| Reasons for antithrombotics medication, n (%) |                   |                              |         |
| Ischemic stroke                | 2 (2.6)                     | 9 (4.3)                      | 0.53    |
| Ischemic heart disease         | 2 (2.6)                     | 4 (1.9)                      |         |
| Atrial fibrillation or other cardiac disease | 4 (5.1) | 4 (1.9) |         |
| Others*                        | 8 (10.3)                    | 22 (10.5)                    |         |
| Hemorrhagic stroke, n (%)      | 3 (3.8)                     | 3 (1.4)                      | 0.35    |
| Time from ictus to CT scan <3 hours, n (%) | 55 (70.5) | 138 (66.0) | 0.47    |
| Hematocrit (%), mean±SD        | 38.8±5.5                    | 40.0±5.5                     | 0.09    |
| INR ≥1.8, n (%)                | 5 (6.4)                     | 3 (1.4)                      | 0.037   |
| GPT ≥40 IU, n (%)              | 20 (25.6)                   | 28 (13.4)                    | 0.013   |
| Location of hematoma, n (%)    |                             |                              | 0.35    |
| Deep                           | 65 (83.3)                   | 183 (87.6)                   |         |
| Lobar                          | 13 (16.7)                   | 26 (12.4)                    |         |
| Hemorrhage volume ≥30 mL, n (%)| 32 (41.0)                   | 60 (28.7)                    | 0.047   |
| Intraventricular extension, n (%)| 33 (42.8) | 95 (45.5) | 0.63    |
| Spot sign, n (%)               | 25 (32.1)                   | 15 (7.2)                     | <0.001  |
| Time to target blood pressure (hour), n (%) |                   |                              | 0.75    |
| <1                             | 46 (59.0)                   | 130 (62.2)                   |         |
| ≥ 1 and <3                    | 22 (28.2)                   | 57 (27.3)                    |         |
| ≥ 3 and <6                    | 7 (9.0)                     | 18 (8.6)                     |         |
| ≥6                            | 3 (3.8)                     | 4 (1.9)                      |         |
| Neurologic deterioration, n (%)| 8 (10.3)                    | 12 (5.7)                     | 0.18    |
| Hematoma evacuation, n (%)     | 44 (56.4)                   | 64 (30.6)                    | <0.001  |
| Death within 1 month, n (%)    | 15 (19.2)                   | 19 (9.1)                     | 0.018   |

*pPrimary prevention of cerebrovascular or cardiovascular or peripheral vessel event. †Time from arrival to goal of blood pressure according to our center’s guideline. ICH: intracerebral hemorrhage, SD: standard deviation, INR: international normalized ratio, GPT: alanine transaminase.

### Table 3. Predictors of CTA spot sign in acute spontaneous ICH

| Factors                        | Spot sign | OR (95% CI) | p value |
|--------------------------------|-----------|-------------|---------|
| Time from ictus to CT scan <3 hours | 5.14 (1.76-15.02) | 0.003 |
| Hemorrhage volume ≥30 mL          | 1.61 (0.79-3.31) | 0.193 |
| Intraventricular extension         | 1.96 (0.95-4.05) | 0.068 |

CTA: CT angiography, ICH: intracerebral hemorrhage, OR: odds ratio, CI: confidence interval.
Hematoma growth

was a marginally significant predictor of hematoma growth

finding that anticoagulant medication was not significantly dif

tient populations and a different sampling design. In contrast to

elevation and hematoma growth in acute ICH may be necessary.

Table 2

Table 4. Predictors of hematoma growth in acute spontaneous ICH

Table 5. Predictors of hematoma expansion within 6 hours in 78 hematoma growth patients

ment in East Asia, and a Korean medical insurance corporation study also showed the association between GPT elevation and ICH occurrence\(^9\). Therefore, further research examining GPT elevation and hematoma growth in acute ICH may be necessary.

Several previous studies have demonstrated an association between warfarin use and hematoma growth\(^3\), but the present study did not show a significant association due to testing different populations and a different sampling design. In contrast to the larger percentage of patients who had used warfarin in the prior study (23.0%)\(^2\), our sample population contained a small proportion of only 7 (2.4%) patients who had used warfarin before ICH development; therefore, the effect of warfarin on the size of hematoma growth might be underestimated in our results (Table 2). One Japanese cohort study was consistent with our finding that anticoagulant medication was not significantly different between patients with and without hematoma growth\(^1\). Moreover, for hemostatic status, an INR elevation of 1.8 or more was a marginally significant predictor of hematoma growth (Table 4, model 1), and an INR ≥1.8 combined with warfarin medi-

cation showed a significant association with hematoma growth (Table 4, model 2). Therefore, a vitamin K antagonist may be a risk factor for hematoma growth in acute ICH.

With regard to antplatelet medication, some investigators have reported increased early hematoma growth, but others could not show that the previous antplatelet medication was associated with hematoma growth in acute ICH\(^5\). In our results, antplatelet medication was a significant risk factor for hyper-acute hematoma growth within 6 hours of ictus (Table 5). An ongoing randomized clinical trial to confirm the efficacy and safety of platelet transfusion in ICH may address this issue\(^2\).

To date, the CTA spot sign and contrast extravasation have not been definitively differentiated as early radiologic markers for hematoma growth in acute ICH\(^1\). Moreover, the CTA spot sign has been variously defined as a foci of enhancement within the hematoma on CTA source images (proposed by Wada et al.)\(^5\), and the criteria have included such characteristics as one or more foci of contrast pooling within the ICH, an attenuation of 120 Hounsfield units or more, a discontinuity from normal or abnormal vasculature adjacent to the ICH, as well as having any size or morphology (suggested by Delgado Almandoz et al.)\(^6\). Compared with the rates of CTA spot sign in studies performed in Western countries (22–41%)\(^9,11,13,19,39\), the spot sign rate in our study (13.9%) was relatively low and in accordance with that of another study in Korea (15%)\(^23\). First, this finding may be attributable to the relatively longer time window of enrollment for patients in our study (as was used in the study by Park et al.)\(^4\) and to the inhomogeneous definition of CTA spot sign compared with the results in the literature\(^9,11,13,19,39\). Second, the first pass CTA may have a lower spot sign detection rate than delayed enhanced CT imaging\(^5\).

Prior studies in Western countries have reported that hematoma growth is a strong predictor of early mortality and poor functional outcome\(^5\). In the current study, hematoma growth increased the probability of early death in acute ICH patients (p=0.018) (Table 2); this finding is consistent with that of another study in Korea\(^2\). Therefore, hematoma growth may be accepted as one of the important predictors of mortality and poor outcome in Korean patients with acute ICH. The 1-month mortality in this study (Table 1) was also comparable to those of other studies for Korean patients with acute ICH\(^2,20\).

This study revealed the association and risk factors between the CTA spot sign and hematoma growth, as well as the clinical impact for early outcome in Korean patients with acute ICH. How-
ever, there were some limitations, including the retrospective study design, multiple testing problems, and a generalizability issue due to the single-center sample.

CONCLUSION

Our results were consistent with those of previous other populations in the way that the CTA spot sign showed a strong probability of being identified in the hyper-acute stage and was an independent strong predictor for hematoma growth in Korean patients with spontaneous ICH. Oral antithrombotics including vitamin K antagonists or antiplatelet drugs might also be associated with hyper-acute hematoma growth in our population. Unlike prior studies, elevated GPT was newly identified as a predictor for hematoma growth and a further prospective study to confirm this association between elevated GPT and hematoma growth in Korean patients with acute ICH.

References

1. Anderson CS, Huang Y, Arima H, Heeley E, Skalina C, Parsons MW, et al.: Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematoma edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke 41: 307-312, 2010
2. Becker KJ, Baxter AB, Bybee HM, Tirschwell DL, Abouelsaad T, Cohen WA: Extravasation of radiographic contrast is an independent predictor of death in primary intracerebral hemorrhage. Stroke 30: 2025-2032, 1999
3. Brouwers HB, Bliffi A, McNamara KA, Ayres AM, Valant V, Schwab K, et al.: Apolipoprotein E genotype is associated with CT angiography spot sign in lobar intracerebral hemorrhage. Stroke 43: 2120-2125, 2012
4. Brouwers HB, Goldstein JN, Romero JM, Rosand J: Clinical applications of the computed tomography angiography spot sign in acute intracerebral hemorrhage: a review. Stroke 43: 3427-3432, 2012
5. Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P: CHANT Investigators: Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 39: 2993-2996, 2008
6. Davis SM, Broderick J, Hemmerici M, Brun NC, Diringer MN, Mayer SA, et al.: Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 66: 1175-1181, 2006
7. de Gans K, de Haan RJ, Majoie CB, Koopman MM, Brand A, Dijkgraaf MG, et al.: PATCH: platelet transfusion in cerebral haemorrhage: study protocol for a multicentre, randomised, controlled trial. BMC Neurol 10: 19, 2010
8. Delcourt C, Huang Y, Arima H, Chalmers J, Davis SM, Heeley EL, et al.: Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. Neurology 79: 314-319, 2012
9. Delgado Almandoz JE, Yoo AJ, Stone MJ, Schafer PW, Goldstein JN, Rosand J, et al.: Systematic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion: the spot sign score. Stroke 40: 2994-3000, 2009
10. Delgado Almandoz JE, Yoo AJ, Stone MJ, Schafer PW, Olenik A, Brouwers HB, et al.: The spot sign score in primary intracerebral hemorrhage identifies highest risk of in-hospital mortality and poor outcome among survivors. Stroke 41: 54-60, 2010
11. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, Molina CA, Blas YS, Dziwolowski I, et al.: Prediction of hematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol 11: 307-314, 2012
12. Dowlatshahi D, Wasserman JK, Monnoli E, Petrich W, Stotts G, Hogan M, et al.: Evolution of computed tomography angiography spot sign is consistent with a site of active hemorrhage in acute intracerebral hemorrhage. Stroke 45: 277-280, 2014
13. Ederies A, Demchuk A, Chia T, Gladstone DJ, Dowlatshahi D, Bendavit G, et al.: Postcontrast CT extravasation is associated with hematoma expansion in CTA spot negative patients. Stroke 40: 1672-1676, 2009
14. Emlet LL, Crippen D: Early recombinant activated factor VII for intracerebral hemorrhage reduced hematoma growth and mortality, while improving functional outcomes. Crit Care 10: 304, 2006
15. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V: Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 8: 355-369, 2009
16. Flaherty ML, Woo D, Haverbusch M, Sekar P, Khoury J, Sauerbeck L, et al.: Racial variations in location and risk of intracerebral hemorrhage. Stroke 36: 934-937, 2005
17. Filbottie JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J: Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 63: 1059-1064, 2004
18. Goldstein JN, Fazen LE, Snider R, Schwab K, Greenberg SM, Smith EE, et al.: Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology 68: 889-894, 2007
19. Halleli H, Abraham AT, Barreto AD, Grotta JC, Savitz SJ: The spot sign in intracerebral hemorrhage: the importance of looking for contrast extravasation. Cerebrovasc Dis 29: 217-220, 2010
20. Huttner HB, Schellinger PD, Hartmann M, Koehrmann M, Juetterl E, Winkle J, et al.: Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 37: 1465-1470, 2006
21. Kim HC, Kang DR, Nam CM, Hur NW, Shim JS, Lee SH, et al.: Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage: Korea medical insurance corporation study. Stroke 36: 1642-1647, 2005
22. Kim HC, Oh SM, Pan WH, Leshima H, Gu D, Chuang XY, et al.: Association between alanine aminotransferase and intracerebral hemorrhage in East Asian populations. Neuroepidemiology 41: 131-138, 2013
23. Kim J, Smith A, Hemphill JC 3rd, Smith WS, Lu Y, Dillon WP, et al.: Contrast extravasation on CT predicts mortality in primary intracerebral hemorrhage. AJNR Am J Neuroradiol 29: 520-525, 2008
24. Kim KH: Predictors of 30-day mortality and 90-day functional recovery after primary intracerebral hemorrhage: hospital based multivariate analysis in 585 patients. J Korean Neurosurg Soc 45: 341-349, 2009
25. Li N, Wang Y, Wang W, Ma L, Xue J, Weissborn K, et al.: Contrast extravasation on computed tomography angiography predicts clinical outcome in primary intracerebral hemorrhage: a prospective study of 139 cases. Stroke 42: 3441-3446, 2011
26. Martí-Fábregas J, Borrell M, Silva Y, Delgado-Mederos R, Martinez-Ramírez S, de Juan-Delago M, et al.: Hemostatic proteins and their association with hematoma growth in patients with acute intracerebral hemorrhage. Stroke 41: 2976-2978, 2010
27. Mayer SA, Brun NC, Bogtrup K, Broderick J, Davis S, Diringer MN, et al.: Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 358: 2127-2137, 2008
28. Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell J, et al.: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II) A randomised trial. Lancet 382: 397-408, 2013
29. Moussouttas M, Malhotra R, Fernandez L, Maltenfort M, Holowecki M, Delgado J, et al.: Role of antiplatelet agents in hematoma expansion dur-
Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke 40: 2398-2401, 2009

Recent epidemiological trends of stroke. J Korean Neurosurg Soc 43: 16-20, 2008

Role of ‘spot sign’ on CT angiography to predict hematoma expansion in spontaneous intracerebral hemorrhage. J Korean Neurosurg Soc 48: 399-405, 2010

Risk factors for computed tomography angiography spot sign in deep and lobar intracerebral hemorrhage are shared. Stroke 45: 1833-1835, 2014

Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol 20: 1277-1283, 2013

Hematoma volume affects the accuracy of computed tomographic angiography ‘spot sign’ in predicting hematoma expansion after acute intracerebral hemorrhage. Eur Neurol 65: 150-155, 2011